Decapeptide-12 vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Decapeptide-12GLP-1 / Weight Loss Agonists
Mazdutide- Summary
- Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Not applicable (topical)
- ~7 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 5 ppm (0.0005%) concentration
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Twice daily (AM and PM)
- Once weekly
- Key Benefits
- Reduces hyperpigmentation and dark spots
- Evens skin tone and improves radiance
- Inhibits post-inflammatory hyperpigmentation
- Well-tolerated alternative to hydroquinone
- Effective for melasma and age spots
- Non-cytotoxic to melanocytes
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Generally very well-tolerated
- Rare mild irritation or sensitivity in some skin types
- Results may take several weeks to become visible
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —